Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Prime Minister Boris Johnson’s top medical adviser, Chris Whitty, said on Wednesday that data on the extent and impact of the outbreak was encouraging but that it was too soon to focus the next phase of the government’s response. “Our view is that it is probably reaching the peak overall,” Whitty said at the government’s daily news conference. “We are not yet at the point where we can say confidently and safely ‘this is now past the peak and we can start thinking very much now about the next phases.’”  So far, more than 12,868 people with COVID-19 have died in British hospitals, though new official data indicates the true death toll could be much larger. Whitty said the daily number of deaths could rise in coming days due reporting lags. The government is widely expected to announce on Thursday that it will extend the most far-reaching restrictions on daily life in Britain’s peacetime history. But Johnson had initially refrained from approving the stringent controls that other European leaders imposed. He later closed down the country when projections showed a quarter of a million people could die in the United Kingdom. The leader of the opposition Labour Party, Keir Starmer, said the prime minister had initially been too slow to impose the lockdown, signalling the political row that is likely to dominate the national discourse for years to come. “I am worried that it looks like we are going to have a higher death rate than any other country in Europe and there will obviously be searching questions about why that has happened,” Starmer told LBC radio. “I did think the government was going too slowly,” Starmer said. “We will have to look back in due course.”  A widespread lockdown came into force on March 23. Prior to that the Conservative government had urged people not to make unnecessary journeys and to cut down on socialising, rather than closing establishments down. But Britons had still packed pubs and restaurants, and even the Cheltenham horse-racing event went ahead, bringing together thousands of punters. Johnson even joked about shaking hands with medical staff during a hospital visit. Starmer, a 57-year-old former prosecutor who won the Labour Party leadership earlier this month, also called on the government to publish its exit strategy from lockdown restrictions. Foreign minister Dominic Raab, who is deputising for Johnson while he recovers from COVID-19, will lead a cabinet meeting on Thursday morning, and in the afternoon chair an emergency response committee meeting to decide on extending the lockdown   The United Kingdom’s hospital death toll from COVID-19 rose by 761 to 12,868 as of 1600 on April 14, the health ministry said. The toll had gone up by 778 the previous day. The official British death toll is the fifth-highest globally after the United States, Italy, Spain and France. The United States has reported more than 28,000 deaths while Italy has reported more than 21,000. Several European countries have announced plans or already begun to relax restrictions, balancing the risk of reversing gains against further damage to battered economies. Starmer said Labour supported extending the measures in Britain but that to “maintain morale and hope”, the public needed to have an idea of what is coming next. Government officials have defended their course of action regarding the start of the lockdown and said it would be a mistake to talk about how to end the lockdown before they were confident the peak had been reached. Amid the doom, though, there were rays of hope. A 106-year-old woman, thought to be the oldest patient in Britain to beat the novel coronavirus, was discharged from hospital. Connie Titchen, born in 1913, had battled suspected pneumonia and COVID-19. A 99-year-old war veteran, Tom Moore, has raised more than 8 million pounds ($10.03 million) for Britain’s health service with a walk around his garden.
[EX A]: UK virus outbreak 'probably' peaking, but too soon to ease lockdown.

[EX Q]: Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.
[EX A]: Eli Lilly drops inhaled insulin program.

[EX Q]: The study, which underscored the importance of social distancing to fight the coronavirus outbreak, looked at 243 cases of COVID-19, the illness caused by the coronavirus, reported in Singapore between January 23 and March 16. It identified seven “clusters” where pre-symptomatic transmission was likely, and in four such groups, where the date of exposure could be determined, pre-symptomatic transmission occurred one-to-three days before symptoms appeared in the source patient. Of the cases in Singapore, 157 were locally acquired and 10 of these were likely transmitted before symptoms started to show. The fast-spreading virus has claimed over 43,000 lives globally, with nearly 4,000 in the United States. The findings suggest that it might not be enough for people showing symptoms to limit their contact to control the pandemic, the researchers wrote in the CDC’s Morbidity and Mortality Weekly Report, published online on Wednesday. The findings increase the challenges of containment measures, the researchers wrote, but said the magnitude of the impact depends on the extent and duration of transmissibility while a patient is pre-symptomatic and that has so far not been clearly established. The study authors suggested that public health officials conducting contact tracing should strongly consider including a period before symptom onset to account for the possibility of this type of transmission. Transmissions might take place through respiratory droplets or even speech and other vocal activities such as singing, with the rate of emission corresponding to voice loudness, according to the researchers. While the cases were carefully investigated, the CDC said it was possible an unknown source might have caused the clusters. And, the findings could also be affected by incorrect reporting of cases, especially if people had only mild symptoms. With the focus currently on testing only people who show symptoms, the researchers expect asymptomatic illness to be under-detected. Still, the CDC data adds to previous reports of individual cases in China that indicated the virus could spread before symptoms start to appear.
[EX A]:
Coronavirus can spread one to three days before symptoms appear: CDC study.